Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population.

Katherine K CliftonYi MinJ KimmelJ LittonD TripathyM Karuturi

Published in: Breast cancer research and treatment (2019)

Palbociclib was well tolerated in the geriatric population and there was no difference in PFS between older and younger patients. These results are reassuring as palbociclib becomes the frontline standard of care therapy for patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
free survival
healthcare
prognostic factors
peritoneal dialysis
patient reported outcomes
quality improvement
community dwelling